Navigation Links
Computational Model Reveals Working of AZT in Body

A computational model has been developed by researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech which would allow scientists to have a better //understanding of the metabolism and toxicity of the HIV/AIDS drug zidovudine (azidothymidine, AZT).

AZT is used successfully as part of Highly Active Anti-Retroviral Therapy (HAART) to control the level of the human immunodeficiency virus in HIV-infected individuals. However, long-term use of AZT may lead to side-effects in some patients. David Samuels and coworkers are interested in finding out whether the toxic side effects of AZT can eventually be minimized or even eliminated. For this purpose, they have been developing a detailed computational model that allows scientists to simulate the biochemical reactions that take place when AZT is metabolized in cells, including their mitochondria, under different metabolic conditions. Drugs like AZT may interfere with DNA replication in the mitochondria, the energy factories of our cells, and can lead to potentially fatal side effects in patients undergoing HAART treatment.

Samuels, assistant professor at VBI, commented: "HAART is one of the biggest success stories in modern medicine. The goal of our work is to help improve this successful treatment by understanding the toxic effects that AZT can have in some people. There are many different ways that AZT could possibly interfere with mitochondria to cause the toxic side-effects. Our job is to model these proposed toxicity mechanisms to see which ones could actually lead to the mitochondrial defects found in AIDS patients." He added: "It is possible that no single mechanism is responsible for the toxicity, but that instead a combination of multiple effects is needed. That is the kind of problem that needs a systems biology approach."

When AZT reaches a cell, it is subject to some of the same metabolic modifications or phosphorylation events that are encountered by the four natu rally occurring deoxynucleosides, the building blocks used to make DNA. However, modified AZT molecules lack a specific chemical group (a hydroxyl group) that would allow DNA replication to continue. This results in premature termination of DNA synthesis. It is thought that the triphosphorylated form of AZT can enter the mitochondrial matrix, the inner core of the mitochondrion, and disrupt the replication of mitochondrial DNA by prematurely terminating DNA synthesis.

Samuels added: "We're just starting our work. It is too early to say what the mechanism of mitochondrial toxicity of AZT is. The inhibition of deoxynucleoside metabolism is one possibility. The incorporation of AZT into mitochondrial DNA is another." He added: "The detailed computational model that we have developed should allow researchers to explore different hypotheses as to why AZT can lead to such debilitating side effects in some patients undergoing anti-retroviral treatment."

Source: Eurekalert
'"/>




Related medicine news :

1. Researchers Develop Mouse Model Of Brain Tumor
2. New Model for understanding Tumor Metastasis
3. Mathematical Model Can Now Help Predict Asthma Risk
4. Model Kate Moss - Re-Birth After Humiliation
5. Womens Self-Esteem Not Lowered By Seeing Ultra Thin Models
6. India Can Become A Role Model In Combating HIV Infections
7. Mouse Models To Determine The Cause Of Aggressive Leukemia
8. Aussie Model Macpherson Hated Tall Figure
9. Mouse Model Beneficial to Study of Head and Neck Cancer
10. Tamil Nadu Emerging As Model State In Public Health Care: Governor
11. iSTART Brain Model Reveals the possible Cause of Autism
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, and Omega ... Omega Station” is the creation of published author, Chris Jackson. Chris Jackson grew ... works in the Dallas Independent School District teaching English. He is heavily involved in ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical ... for the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed ... product advances towards regulatory and clinical phases. , "This is another important step ...
(Date:4/22/2017)... (PRWEB) , ... April 22, 2017 , ... Ecommerce sales ... United States estimated to be $394.9 billion. The consequences of rapid innovation and ... demolishes) the limits of technology, it is every business and individual’s job to give ...
(Date:4/22/2017)... , ... April 22, 2017 , ... The San Juan Capistrano summer camp ... parenting report outlining the need for summer camps to provide physical activities for all campers. ... Physical Activity In Summer Camps , With an increase in specialty camps that focus on ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to popular ... violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and his ... in violence in the United States. The study, Trends in Fighting and ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology: